辅助药物改善局部治疗后的生存。

StephenW

J Vasc Interv Radiol. 2017 May 17. pii: S1051-0443(17)30418-9. doi: 10.1016/j.jvir.2017.04.016. [Epub ahead of print]
Adjuvant Medications That Improve Survival after Locoregional Therapy.Boas FE1, Ziv E2, Yarmohammadi H2, Brown KT2, Erinjeri JP2, Sofocleous CT2, Harding JJ3, Solomon SB2.
Author information

AbstractPURPOSE: To determine if outpatient medications taken at the time of liver tumor embolization or ablation affect survival.
MATERIALS AND METHODS: A retrospective review was done of 2,032 liver tumor embolization, radioembolization, and ablation procedures performed in 1,092 patients from June 2009 to April 2016. Pathology, hepatocellular carcinoma (HCC) stage (American Joint Committee on Cancer), neuroendocrine tumor (NET) grade, initial locoregional therapy, overall survival after initial locoregional therapy, Child-Pugh score, Eastern Cooperative Oncology Group performance status, Charlson Comorbidity Index, and outpatient medications taken at the time of locoregional therapy were analyzed for each patient. Kaplan-Meier survival curves were calculated for patients taking 29 medications or medication classes (including prescription and nonprescription medications) for reasons unrelated to their primary cancer diagnosis. Kaplan-Meier curves were compared using the log-rank test.
RESULTS: For patients with HCC initially treated with embolization (n = 304 patients), the following medications were associated with improved survival when taken at the time of embolization: beta-blockers (P = .0007), aspirin (P = .0008) and other nonsteroidal antiinflammatory drugs (P = .009), proton pump inhibitors (P = .004), and antivirals for hepatitis B or C (P = .01). For colorectal liver metastases initially treated with ablation (n = 172 patients), beta-blockers were associated with improved survival when taken at the time of ablation (P = .02).
CONCLUSIONS: Aspirin and beta-blockers are associated with significantly improved survival when taken at the time of embolization for HCC. Aspirin was not associated with survival differences after locoregional therapy for NET or colorectal liver metastases, suggesting an HCC-specific effect.


Copyright © 2017 SIR. Published by Elsevier Inc. All rights reserved.



PMID:28527884DOI:10.1016/j.jvir.2017.04.016

• 
  


• 
  

StephenW

J Vasc Interv Radiol。 2017年5月17日。pii：S1051-0443（17）30418-9。 doi：10.1016 / j.jvir.2017.04.016。 [提前印刷]
辅助药物改善局部治疗后的生存。
Boas FE1，Ziv E2，Yarmohammadi H2，Brown KT2，Erinjeri JP2，Sofocleous CT2，Harding JJ3，Solomon SB2。
作者信息

1
    介入放射学服务部放射科，纪念斯隆凯特琳癌症中心，约克大街1275号，纽约，纽约10065.电子地址：[email protected]。
2
    介入放射学服务部放射科，纪念斯隆凯特琳癌症中心，约克大街1275号，纽约，纽约10065。
3
    胃肠道医学肿瘤学系，医学系，纪念斯隆凯特琳癌症中心，纽约纽约大道1275号纽约10065;美国纽约纽约威尔康奈尔医学院医学系。

抽象
目的：

确定在肝肿瘤栓塞或消融时采取的门诊药物是否影响生存。
材料和方法：

2009年6月至2016年4月在1,092例患者中进行了2032例肝肿瘤栓塞，放射栓塞和消融手术的回顾性回顾。病理学，肝细胞癌（HCC）阶段（美国癌症联合委员会），神经内分泌肿瘤（NET）对每位患者进行初步局部治疗，初步局部治疗后的总生存期，Child-Pugh评分，东部合作肿瘤组表现状态，Charlson合并症指数和局部治疗时采取的门诊药物。与其原发性癌症诊断无关的原因，计算29例药物或药物治疗类别（包括处方药和非处方药）的患者的Kaplan-Meier生存曲线。使用对数秩检验比较Kaplan-Meier曲线。
结果：

对于首先用栓塞治疗的患者（n = 304例患者），以下药物与栓塞时的生存率有改善有关：β-受体阻滞剂（P = 0.0007），阿司匹林（P = 0.0008）等非甾体抗炎药（P = 0.009），质子泵抑制剂（P = 0.004），以及用于B型肝炎或C（P = 0.01）的抗病毒药物。对于最初与消融（N = 172名患者）治疗结直肠癌肝转移，当在消融的时间（P = 0.02）拍摄的β受体阻滞剂，用改进的存活相关。
结论：

阿司匹林和β-阻滞剂与HCC栓塞时的生存率有显着改善。阿司匹林与NET或结肠直肠肝转移的局部治疗后的生存差异无关，提示HCC特异性作用。

版权所有©2017 SIR。由Elsevier Inc.发布。保留所有权利。

结论：
    28527884
DOI：
    10.1016 / j.jvir.2017.04.016


DOI：
    10.1016 / j.jvir.2017.04.016